AlphaMaven

Company Logo'

Hedge Fund

Quantitative Tactical Aggressive Fund LLC

Quantitative Investment Management
Request More Information

Investment Overview

Strategy Description

Quantitative Investment Management, LLC is a Virginia-based global investment management firm specializing in alternative investment strategies for institutional and private investors. QIM was founded in 2003 by Jaffray Woodriff, Michael Geismar and Greyson Williams. Our firm develops proprietary frameworks for predicting short- and medium-term price movements for a wide variety of markets. We currently employ numerous quantitative trading models that utilize pattern recognition to predict the global equity and futures markets. The Quantitative Tactical Aggressive Fund is a long/short equity hedge fund.
Principals

John Coleman
John Coleman - Director, Investor Relations and Marketing, Quantitative Investment Management
Investment Highlights

Investment Category

Hedge Fund

Investment Strategy

Long/Short Equity

Investment Structure

Fund
Implementation of Strategy
Tactical Approach

Market Sector Exposure

Equities

Instruments Traded

Public Equity
Investment Structure

Legal Structure

LLC

Fund Minimum Investment

Please Login for More

Strategy AUM

$336MM

Firm AUM

$1.1B

Incentive Fee (%)

30%
Service Providers
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.
You May Also Enjoy The Following Posts
Andrea Alms Video:  Money In Motion 101 - Deep Dive - Immunotherapy Cancer Market
2w ago PrivateEquity BrookDell Partners
Andrea Alms Video:  Money In Motion 98 - Radiation Therapy Market
1mo ago PrivateEquity BrookDell Partners
Andrea Alms Video:  Money In Motion 96 - Bone Marrow Transplantation Market
1mo ago PrivateEquity BrookDell Partners
Ridgedale MSP Partner Series - March 2024 Newsletter
6d ago HedgeFund Ridgedale MSP Partner Series
Exome Worldwide Healthcare Partners - March 2024 Investor Newsletter
2w ago HedgeFund Worldwide Healthcare Partners
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.